Beta-synuclein is a protein encoded by SNCB gene and is highly homologous to alpha synuclein. However it is not found in Lewy bodies as alpha synuclein, but it is found in neurofibrillary tangles in patients with Alzheimer's disease. Beta synuclein is enriched in presynaptic terminals and appears be able to block alpha synuclein aggregation and may act as a protective chaperone in this way. Beta synuclein also protects neurons from staurosporine and 6-hydroxy-dopamine induced apoptosis and thus the protein is thought to have anti-apoptotic activity. As a partner for alpha synuclein research, Biosensis is pleased to offer a new purified and published polyclonal antibody to beta synuclein protein. Our catalog number R-1683-500 is made to the C terminal domain (aa99-113) of human beta synuclein and has been successfully tested in western blots and immunohistochemistry. The antibody is highly specific to beta synuclein and does not cross with alpha synuclein in western blots or in immunohistochemistry on Lewy bodies or normal tissue.
Description
|
Catalog No
|
Price (USD)
|
Rabbit antibody to beta synuclein (C-terminal domain): IgG
|
|
$287.00
|
This new antibody complements our existing line of Beta synuclein antibodies and hopefully provides researchers with even more choices for their beta synuclein research in both health and pathological conditions.

Image: Western Immunoblotting of human β-synuclein protein in human brain homogenate, 10 μg protein per lane. Crude anti-beta-synuclein ab (Catalog Number R-1683-100) used at 1:1000. Peptide absorption reduced antibody reactivity for expected beta-synuclein band of 17 kDa.
References:
1. K.K. Ia et al (2011) Defining the substrate specificity determinants recognized by the active site of C-Terminal Src Kinase-Homologous Kinase (CHK) and identification of β-Synuclein as a potential CHK physiological substrate. Biochemistry, 50, 6667-6677.
2. S. George et al (2010) α-Synuclein transgenic mice reveal compensatory increases in Parkinson's Disease-associated proteins DJ-1 and Parkin and have enhanced α-synuclein and PINK1 levels after rotenone treatment. J. Mol. Neurosci. 42, 243-254.
3. M.C. Quilty et al (2003) Localization of alpha-, beta-, and gamma-synuclein during neuronal development and alterations associated with the neuronal response to axonal trauma. Exp Neurol 182, 195-207.
4. Q.X. Li et al (2002) Platelet alpha- and gamma-synucleins in Parkinson's disease and normal control subjects. Journal of Alzheimer's Disease 4, 309-315.
5. J.G. Culvenor et al (2002) Oligodendrocytes from neural stem cells express alpha-synuclein: Increased numbers from Presenilin 1 deficient mice. NeuroReport 13, 1305-1308.
6. J.G. Culvenor et al (1999) Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited: NAC and alpha-synuclein are not associated with Abeta amyloid. Am. J. Path. 155, 1173-1181.